Lab Notes: Chimeron Bio names new CEO; Amicus Therapeutics gets positive opinion for rare disease therapy

This week's Philadelphia-area life sciences industry news includes a biotechnology firm naming a new CEO, positive study results on an experimental cancer therapy for another, progress on a potential treatment for a rare disorder for a third, and more. Here is the roundup: The Philadelphia biotechnology company developing self-amplifying RNA vaccines and therapeutics has named Kevin Heyeck as its new CEO. He succeeds former chief executive Jolly Mazumdar, who departed the post earlier this month …
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Source Type: news